ImmuCell Corporation
ICCC
$6.25
$0.1652.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.75% | 28.29% | 51.63% | 46.37% | 48.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.75% | 28.29% | 51.63% | 46.37% | 48.05% |
| Cost of Revenue | 3.82% | 20.17% | 38.77% | 40.10% | 52.51% |
| Gross Profit | 67.15% | 47.19% | 89.89% | 64.43% | 37.84% |
| SG&A Expenses | 3.90% | 14.10% | 8.81% | -2.10% | -0.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.64% | 10.47% | 22.18% | 20.39% | 27.08% |
| Operating Income | 163.95% | 105.65% | 76.38% | 52.70% | 35.90% |
| Income Before Tax | 143.83% | 93.29% | 62.80% | 39.57% | 32.69% |
| Income Tax Expenses | 170.73% | 144.19% | 120.00% | 10.64% | -51.19% |
| Earnings from Continuing Operations | 143.51% | 93.03% | 62.65% | 39.53% | 32.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 143.51% | 93.03% | 62.65% | 39.53% | 32.71% |
| EBIT | 163.95% | 105.65% | 76.38% | 52.70% | 35.90% |
| EBITDA | 862.91% | 635.69% | 158.07% | 98.42% | 76.03% |
| EPS Basic | 136.16% | 87.42% | 62.31% | 40.31% | 32.93% |
| Normalized Basic EPS | 137.67% | 87.21% | 67.86% | 46.96% | 28.70% |
| EPS Diluted | 134.48% | 85.84% | 61.08% | 38.77% | 31.88% |
| Normalized Diluted EPS | 137.67% | 87.21% | 67.86% | 46.96% | 28.70% |
| Average Basic Shares Outstanding | 13.05% | 9.34% | 5.39% | 1.57% | 0.23% |
| Average Diluted Shares Outstanding | 13.05% | 9.34% | 5.39% | 1.57% | 0.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |